{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:32:45Z","timestamp":1778110365019,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00108-025-01897-2","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T09:57:15Z","timestamp":1745575035000},"page":"475-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Medikament\u00f6se Adipositastherapie in Deutschland","Pharmacotherapy of obesity in Germany"],"prefix":"10.1007","volume":"66","author":[{"given":"Matthias","family":"Bl\u00fcher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"1897_CR1","unstructured":"(2024) Deutsche Adipositas-Gesellschaft (DAG) e.\u202fV. S3-Leitlinie Adipositas \u2013 Pr\u00e4vention und Therapie. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/050-001. Zugegriffen: 5. M\u00e4rz 2025"},{"issue":"3","key":"1897_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD M\u00fcller","year":"2022","unstructured":"M\u00fcller\u00a0TD, Bl\u00fcher\u00a0M, Tsch\u00f6p\u00a0MH, DiMarchi\u00a0RD (2022) Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 21(3):201\u2013223","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"1897_CR3","first-page":"629","volume":"64","author":"TD M\u00fcller","year":"2023","unstructured":"M\u00fcller\u00a0TD, Bl\u00fcher\u00a0M (2023) Obesity treatment: will pharmacotherapies replace metabolic surgery in the future? Inn Med 64(7):629\u2013635","journal-title":"Inn Med"},{"issue":"24","key":"1897_CR4","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff\u00a0AM, Brown-Frandsen\u00a0K, Colhoun\u00a0HM, Deanfield\u00a0J, Emerson\u00a0SS, Esbjerg\u00a0S, Hardt-Lindberg\u00a0S, Hovingh\u00a0GK, Kahn\u00a0SE, Kushner\u00a0RF, Lingvay\u00a0I, Oral\u00a0TK, Michelsen\u00a0MM, Plutzky\u00a0J, Torn\u00f8e\u00a0CW, Ryan\u00a0DH (2023) SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N\u00a0Engl J Med 389(24):2221\u20132232","journal-title":"N Engl J Med"},{"issue":"8","key":"1897_CR5","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/dom.15077","volume":"25","author":"M Bl\u00fcher","year":"2023","unstructured":"Bl\u00fcher\u00a0M, Aras\u00a0M, Aronne\u00a0LJ, Batterham\u00a0RL, Giorgino\u00a0F, Ji\u00a0L, Pietil\u00e4inen\u00a0KH, Schnell\u00a0O, Tonchevska\u00a0E, Wilding\u00a0JPH (2023) New insights into the treatment of obesity. Diabetes Obes Metab 25(8):2058\u20132072","journal-title":"Diabetes Obes Metab"},{"issue":"10471","key":"1897_CR6","first-page":"2543","volume":"404","author":"Global Nutrition Target Collaborators","year":"2025","unstructured":"Global Nutrition Target Collaborators (2025) Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a\u00a0systematic analysis for the Global Burden of Disease Study 2021. Lancet 404(10471):2543\u20132583","journal-title":"Lancet"},{"issue":"3","key":"1897_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino\u00a0F, Cummings\u00a0DE, Eckel\u00a0RH, Cohen\u00a0RV, Wilding\u00a0JPH, Brown\u00a0WA, Stanford\u00a0FC, Batterham\u00a0RL, Farooqi\u00a0IS, Farpour-Lambert\u00a0NJ, le Roux\u00a0CW, Sattar\u00a0N, Baur\u00a0LA, Morrison\u00a0KM, Misra\u00a0A, Kadowaki\u00a0T, Tham\u00a0KW, Sumithran\u00a0P, Garvey\u00a0WT, Kirwan\u00a0JP, Fern\u00e1ndez-Real\u00a0JM, Corkey\u00a0BE, Toplak\u00a0H, Kokkinos\u00a0A, Kushner\u00a0RF, Branca\u00a0F, Valabhji\u00a0J, Bl\u00fcher\u00a0M, Bornstein\u00a0SR, Grill\u00a0HJ, Ravussin\u00a0E, Gregg\u00a0E, Al Busaidi\u00a0NB, Alfaris\u00a0NF, Al Ozairi\u00a0E, Carlsson\u00a0LMS, Cl\u00e9ment\u00a0K, Despr\u00e9s\u00a0JP, Dixon\u00a0JB, Galea\u00a0G, Kaplan\u00a0LM, Laferr\u00e8re\u00a0B, Laville\u00a0M, Lim\u00a0S, Fuentes\u00a0LJR, Mooney\u00a0VM, Nadglowski\u00a0J Jr, Urudinachi\u00a0A, Olszanecka-Glinianowicz\u00a0M, Pan\u00a0A, Pattou\u00a0F, Schauer\u00a0PR, Tsch\u00f6p\u00a0MH, van der Merwe\u00a0MT, Vettor\u00a0R, Mingrone\u00a0G (2025) Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 13(3):221\u2013262","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1897_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11428-024-01167-z","volume":"3","author":"P Roser","year":"2024","unstructured":"Roser\u00a0P (2024) Pharmakotherapie der Adipositas. Die Diabetol 3:340\u2013348","journal-title":"Die Diabetol"},{"issue":"3","key":"1897_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1592\/phco.20.4.270.34882","volume":"20","author":"AM Heck","year":"2000","unstructured":"Heck\u00a0AM, Yanovski\u00a0JA, Calis\u00a0KA (2000) Orlistat, a\u00a0new lipase inhibitor for the management of obesity. Pharmacotherapy 20(3):270\u2013279","journal-title":"Pharmacotherapy"},{"issue":"9123","key":"1897_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","volume":"352","author":"L Sj\u00f6str\u00f6m","year":"1998","unstructured":"Sj\u00f6str\u00f6m\u00a0L, Rissanen\u00a0A, Andersen\u00a0T, Boldrin\u00a0M, Golay\u00a0A, Koppeschaar\u00a0HP, Krempf\u00a0M (1998) Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 352(9123):167\u2013172","journal-title":"Lancet"},{"issue":"1","key":"1897_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson\u00a0JS, Hauptman\u00a0J, Boldrin\u00a0MN, Sj\u00f6str\u00f6m\u00a0L (2004) XENical in the prevention of diabetes in obese subjects (XENDOS) study: a\u00a0randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type\u00a02 diabetes in obese patients. Diabetes Care 27(1):155\u2013161","journal-title":"Diabetes Care"},{"key":"1897_CR12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","volume":"142","author":"Z Li","year":"2005","unstructured":"Li\u00a0Z, Maglione\u00a0M, Tu\u00a0W, Mojica\u00a0W, Arterburn\u00a0D, Shugarman\u00a0LR, Hilton\u00a0L, Suttorp\u00a0M, Solomon\u00a0V, Shekelle\u00a0PG, Morton\u00a0SC (2005) Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142:532\u2013546","journal-title":"Ann Intern Med"},{"key":"1897_CR13","first-page":"60","volume":"12","author":"M Bl\u00fcher","year":"2018","unstructured":"Bl\u00fcher\u00a0M (2018) Naltrexon\/Bupropion in der Adipositastherapie. Adipositas 12:60\u201367","journal-title":"Adipositas"},{"key":"1897_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway\u00a0FL, Fujioka\u00a0K, Plodkowski\u00a0RA, Mudaliar\u00a0S, Guttadauria\u00a0M, Erickson\u00a0J, Kim\u00a0DD, Dunayevich\u00a0E, COR\u2011I Study Group (2010) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a\u00a0multicentre, randomised, double-blind, placebo-controlled, phase\u00a03\u00a0trial. Lancet 376:595\u2013605","journal-title":"Lancet"},{"key":"1897_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller\u00a0TD, Finan\u00a0B, Bloom\u00a0SR, D\u2019Alessio\u00a0D, Drucker\u00a0DJ, Flatt\u00a0PR, Fritsche\u00a0A, Gribble\u00a0F, Grill\u00a0HJ, Habener\u00a0JF, Holst\u00a0JJ, Langhans\u00a0W, Meier\u00a0JJ, Nauck\u00a0MA, Perez-Tilve\u00a0D, Pocai\u00a0A, Reimann\u00a0F, Sandoval\u00a0DA, Schwartz\u00a0TW, Seeley\u00a0RJ, Stemmer\u00a0K, Tang-Christensen\u00a0M, Woods\u00a0SC, DiMarchi\u00a0RD, Tsch\u00f6p\u00a0MH (2019) Glucagon-like peptide 1 (GLP-1). Mol Metab 30:72\u2013130","journal-title":"Mol Metab"},{"issue":"1","key":"1897_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"SCALE Obesity and Prediabetes NN8022-1839 Study Group, Pi-Sunyer\u00a0X et\u00a0al (2015) A randomized, controlled trial of 3.0\u202fmg of Liraglutide in weight management. N\u00a0Engl J Med 373(1):11\u201322","journal-title":"N Engl J Med"},{"key":"1897_CR17","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux\u00a0CW, Astrup\u00a0A, Fujioka\u00a0K, Greenway\u00a0F, Lau\u00a0DCW, Van Gaal\u00a0L, Ortiz\u00a0RV, Wilding\u00a0JPH, Skj\u00f8th\u00a0TV, Manning\u00a0LS, Pi-Sunyer\u00a0X, SCALE Obesity Prediabetes NN8022-1839 Study Group (2017) 3\u00a0years of liraglutide versus placebo for type\u00a02 diabetes risk reduction and weight management in individuals with prediabetes: a\u00a0randomised, double-blind trial. Lancet 389:1399\u20131409","journal-title":"Lancet"},{"issue":"22","key":"1897_CR18","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly\u00a0AS, Auerbach\u00a0P, Barrientos-Perez\u00a0M, Gies\u00a0I, Hale\u00a0PM, Marcus\u00a0C, Mastrandrea\u00a0LD, Prabhu\u00a0N, Arslanian\u00a0S, NN8022-4180 Trial Investigators (2020) A\u00a0Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N\u00a0Engl J Med 382(22):2117\u20132128","journal-title":"N Engl J Med"},{"issue":"2","key":"1897_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino\u00a0DM, Greenway\u00a0FL, Khalid\u00a0U, O\u2019Neil\u00a0PM, Rosenstock\u00a0J, S\u00f8rrig\u00a0R, Wadden\u00a0TA, Wizert\u00a0A, Garvey\u00a0WT, STEP 8 Investigators. (2022) Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA 327(2):138\u2013150","journal-title":"JAMA"},{"issue":"6","key":"1897_CR20","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/oby.22794","volume":"28","author":"RF Kushner","year":"2020","unstructured":"Kushner\u00a0RF, Calanna\u00a0S, Davies\u00a0M, Dicker\u00a0D, Garvey\u00a0WT, Goldman\u00a0B, Lingvay\u00a0I, Thomsen\u00a0M, Wadden\u00a0TA, Wharton\u00a0S, Wilding\u00a0JPH, Rubino\u00a0D (2020) Semaglutide 2.4\u202fmg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obes 28(6):1050\u20131061","journal-title":"Obes"},{"issue":"11","key":"1897_CR21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding\u00a0JPH, Batterham\u00a0RL, Calanna\u00a0S, Davies\u00a0M, Van Gaal\u00a0LF, Lingvay\u00a0I, McGowan\u00a0BM, Rosenstock\u00a0J, Tran\u00a0MTD, Wadden\u00a0TA, Wharton\u00a0S, Yokote\u00a0K, Zeuthen\u00a0N, Kushner\u00a0RF (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. N\u00a0Engl J Med 384(11):989\u20131002","journal-title":"N Engl J Med"},{"issue":"8","key":"1897_CR22","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding\u00a0JPH, Batterham\u00a0RL, Davies\u00a0M, Van Gaal\u00a0LF, Kandler\u00a0K, Konakli\u00a0K, Lingvay\u00a0I, McGowan\u00a0BM, Oral\u00a0TK, Rosenstock\u00a0J, Wadden\u00a0TA, Wharton\u00a0S, Yokote\u00a0K, Kushner\u00a0RF (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1\u00a0trial extension. Diabetes Obes Metab 24(8):1553\u20131564","journal-title":"Diabetes Obes Metab"},{"issue":"10278","key":"1897_CR23","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies\u00a0M, F\u00e6rch\u00a0L, Jeppesen\u00a0OK, Pakseresht\u00a0A, Pedersen\u00a0SD, Perreault\u00a0L, Rosenstock\u00a0J, Shimomura\u00a0I, Viljoen\u00a0A, Wadden\u00a0TA, Lingvay\u00a0I, STEP 2 Study Group (2021) Semaglutide 2.4\u202fmg once a\u00a0week in adults with overweight or obesity, and type\u00a02 diabetes (STEP\u00a02): a\u00a0randomised, double-blind, double-dummy, placebo-controlled, phase\u00a03\u00a0trial. Lancet 397(10278):971\u2013984","journal-title":"Lancet"},{"issue":"24","key":"1897_CR24","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber\u00a0D, Barrett\u00a0T, Barrientos-P\u00e9rez\u00a0M, Gies\u00a0I, Hesse\u00a0D, Jeppesen\u00a0OK, Kelly\u00a0AS, Mastrandrea\u00a0LD, S\u00f8rrig\u00a0R, STEP TEENS Investigators (2022) Once-Weekly Semaglutide in Adolescents with Obesity. N\u00a0Engl J Med 387(24):2245\u20132257","journal-title":"N Engl J Med"},{"issue":"10","key":"1897_CR25","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar\u00a0N, Lee\u00a0MMY, Kristensen\u00a0SL, Branch\u00a0KRH, Del Prato\u00a0S, Khurmi\u00a0NS, Lam\u00a0CSP, Lopes\u00a0RD, McMurray\u00a0JJV, Pratley\u00a0RE, Rosenstock\u00a0J, Gerstein\u00a0HC (2021) Cardiovascular, mortality, and kidney outcomes with GLP\u20111 receptor agonists in patients with type\u00a02 diabetes: a\u00a0systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9(10):653\u2013662","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1897_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff\u00a0AM, Aronne\u00a0LJ, Ahmad\u00a0NN, Wharton\u00a0S, Connery\u00a0L, Alves\u00a0B, Kiyosue\u00a0A, Zhang\u00a0S, Liu\u00a0B, Bunck\u00a0MC, Stefanski\u00a0A (2022) Tirzepatide Once Weekly for the Treatment of Obesity. N\u00a0Engl J Med 387(3):205\u2013216","journal-title":"N Engl J Med"},{"issue":"10","key":"1897_CR27","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff\u00a0AM, le Roux\u00a0CW, Stefanski\u00a0A, Aronne\u00a0LJ, Halpern\u00a0B, Wharton\u00a0S, Wilding\u00a0JPH, Perreault\u00a0L, Zhang\u00a0S, Battula\u00a0R, Bunck\u00a0MC, Ahmad\u00a0NN, Jouravskaya\u00a0I (2025) Tirzepatide for Obesity Treatment and Diabetes Prevention. N\u00a0Engl J Med 392(10):958\u2013971","journal-title":"N Engl J Med"},{"key":"1897_CR28","doi-asserted-by":"crossref","unstructured":"M\u00fcller TD, Adriaenssens A, Ahr\u00e9n B, Bl\u00fcher M, Birkenfeld A, Campbell JE, Coghlan MP, D\u2019Alessio D, Deacon CF, DelPrato S, Douros JD, Drucker DJ, Figueredo Burgos NS, Flatt PR, Finan B, Gimeno RE, Gribble FM, Hayes MR, H\u00f6lscher C, Holst JJ, Knerr PJ, Knop FK, Kusminski CM, Liskiewicz A, Mabilleau G, Mowery SA, Nauck MA, Novikoff A, Reimann F, Roberts AG, Rosenkilde MM, Samms RJ, Scherer PE, Seeley RJ, Sloop KW, Wolfrum C, Wootten D, DiMarchi RD, Tsch\u00f6p MH (2025) Glucose-dependent insulinotropic polypeptide (GIP). Mol Metab: 102118","DOI":"10.1016\/j.molmet.2025.102118"},{"issue":"1","key":"1897_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7570\/jomes22067","volume":"32","author":"R Sinha","year":"2023","unstructured":"Sinha\u00a0R, Papamargaritis\u00a0D, Sargeant\u00a0JA, Davies\u00a0MJ (2023) Efficacy and Safety of Tirzepatide in Type\u00a02 Diabetes and Obesity Management. J\u00a0Obes Metab Syndr 32(1):25\u201345","journal-title":"J Obes Metab Syndr"},{"issue":"1","key":"1897_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/oby.23612","volume":"31","author":"CW le Roux","year":"2023","unstructured":"le Roux\u00a0CW, Zhang\u00a0S, Aronne\u00a0LJ, Kushner\u00a0RF, Chao\u00a0AM, Machineni\u00a0S, Dunn\u00a0J, Chigutsa\u00a0FB, Ahmad\u00a0NN, Bunck\u00a0MC (2023) Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obes 31(1):96\u2013110","journal-title":"Obes"},{"issue":"13","key":"1897_CR31","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra\u00a0A, Grunstein\u00a0RR, Fietze\u00a0I, Weaver\u00a0TE, Redline\u00a0S, Azarbarzin\u00a0A, Sands\u00a0SA, Schwab\u00a0RJ, Dunn\u00a0JP, Chakladar\u00a0S, Bunck\u00a0MC, Bednarik\u00a0J, SURMOUNT-OSA Investigators (2024) Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N\u00a0Engl J Med 391(13):1193\u20131205","journal-title":"N Engl J Med"},{"issue":"4","key":"1897_CR32","doi-asserted-by":"publisher","first-page":"bvad016","DOI":"10.1210\/jendso\/bvad016","volume":"7","author":"R Mishra","year":"2023","unstructured":"Mishra\u00a0R, Raj\u00a0R, Elshimy\u00a0G, Zapata\u00a0I, Kannan\u00a0L, Majety\u00a0P, Edem\u00a0D, Correa\u00a0R (2023) Adverse Events Related to Tirzepatide. J\u00a0Endocr Soc 7(4):bvad16","journal-title":"J Endocr Soc"},{"issue":"3","key":"1897_CR33","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1056\/NEJMoa1512693","volume":"375","author":"P K\u00fchnen","year":"2016","unstructured":"K\u00fchnen\u00a0P, Cl\u00e9ment\u00a0K, Wiegand\u00a0S, Blankenstein\u00a0O, Gottesdiener\u00a0K, Martini\u00a0LL, Mai\u00a0K, Blume-Peytavi\u00a0U, Gr\u00fcters\u00a0A, Krude\u00a0H (2016) Proopiomelanocortin Deficiency Treated with a\u00a0Melanocortin\u20114 Receptor Agonist. N\u00a0Engl J Med 375(3):240\u2013246","journal-title":"N Engl J Med"},{"issue":"12","key":"1897_CR34","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","volume":"8","author":"K Cl\u00e9ment","year":"2020","unstructured":"Cl\u00e9ment\u00a0K, van den Akker\u00a0E, Argente\u00a0J, Bahm\u00a0A, Chung\u00a0WK, Connors\u00a0H, De Waele\u00a0K, Farooqi\u00a0IS, Gonneau-Lejeune\u00a0J, Gordon\u00a0G, Kohlsdorf\u00a0K, Poitou\u00a0C, Puder\u00a0L, Swain\u00a0J, Stewart\u00a0M, Yuan\u00a0G, Wabitsch\u00a0M, K\u00fchnen\u00a0P, Setmelanotide POMC and LEPR Phase 3 Trial Investigators (2020) Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase\u00a03\u00a0trials. Lancet Diabetes Endocrinol 8(12):960\u2013970","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"1897_CR35","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S2213-8587(22)00277-7","volume":"10","author":"AM Haqq","year":"2022","unstructured":"Haqq\u00a0AM, Chung\u00a0WK, Dollfus\u00a0H, Haws\u00a0RM, Martos-Moreno\u00a0G\u00c1, Poitou\u00a0C, Yanovski\u00a0JA, Mittleman\u00a0RS, Yuan\u00a0G, Forsythe\u00a0E, Cl\u00e9ment\u00a0K, Argente\u00a0J (2022) Efficacy and safety of setmelanotide, a\u00a0melanocortin\u20114 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: a\u00a0multicentre, randomised, double-blind, placebo-controlled, phase\u00a03\u00a0trial with an open-label period. Lancet Diabetes Endocrinol 10(12):859\u2013868","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10403","key":"1897_CR36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop\u00a0FK, Aroda\u00a0VR, do Vale\u00a0RD, Holst-Hansen\u00a0T, Laursen\u00a0PN, Rosenstock\u00a0J, Rubino\u00a0DM, Garvey\u00a0WT, OASIS 1 Investigators (2023) Oral semaglutide 50\u202fmg taken once per day in adults with overweight or obesity (OASIS\u00a01): a\u00a0randomised, double-blind, placebo-controlled, phase\u00a03\u00a0trial. Lancet 402(10403):705\u2013719","journal-title":"Lancet"},{"issue":"10","key":"1897_CR37","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton\u00a0S, Blevins\u00a0T, Connery\u00a0L, Rosenstock\u00a0J, Raha\u00a0S, Liu\u00a0R, Ma\u00a0X, Mather\u00a0KJ, Haupt\u00a0A, Robins\u00a0D, Pratt\u00a0E, Kazda\u00a0C, Konig\u00a0M (2023) Daily Oral GLP\u20111 Receptor Agonist Orforglipron for Adults with Obesity. N\u00a0Engl J Med 389(10):877\u2013888","journal-title":"N Engl J Med"},{"issue":"10317","key":"1897_CR38","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","volume":"398","author":"DCW Lau","year":"2021","unstructured":"Lau\u00a0DCW, Erichsen\u00a0L, Francisco\u00a0AM, Satylganova\u00a0A, le Roux\u00a0CW, McGowan\u00a0B, Pedersen\u00a0SD, Pietil\u00e4inen\u00a0KH, Rubino\u00a0D, Batterham\u00a0RL (2021) Once-weekly cagrilintide for weight management in people with overweight and obesity: a\u00a0multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase\u00a02\u00a0trial. Lancet 398(10317):2160\u20132172","journal-title":"Lancet"},{"key":"1897_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01529-z","author":"AE Henney","year":"2024","unstructured":"Henney\u00a0AE, Wilding\u00a0JPH, Alam\u00a0U, Cuthbertson\u00a0DJ (2024) Obesity pharmacotherapy in older adults: a\u00a0narrative review of evidence. Int J Obes. https:\/\/doi.org\/10.1038\/s41366-024-01529-z","journal-title":"Int J Obes"},{"issue":"3","key":"1897_CR40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","volume":"12","author":"CW le Roux","year":"2024","unstructured":"le Roux\u00a0CW, Steen\u00a0O, Lucas\u00a0KJ, Startseva\u00a0E, Unseld\u00a0A, Hennige\u00a0AM (2024) Glucagon and GLP\u20111 receptor dual agonist survodutide for obesity: a\u00a0randomised, double-blind, placebo-controlled, dose-finding phase\u00a02\u00a0trial. Lancet Diabetes Endocrinol 12(3):162\u2013173","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1897_CR41","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff\u00a0AM, Kaplan\u00a0LM, Fr\u00edas\u00a0JP, Wu\u00a0Q, Du\u00a0Y, Gurbuz\u00a0S, Coskun\u00a0T, Haupt\u00a0A, Milicevic\u00a0Z, Hartman\u00a0ML (2023) Retatrutide Phase\u00a02 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity\u2014A Phase\u00a02 Trial. N\u00a0Engl J Med 389(6):514\u2013526","journal-title":"N Engl J Med"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-01897-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T11:58:45Z","timestamp":1757159925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-01897-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1897"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-01897-2","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"31 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Bl\u00fcher hat Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeit von Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, Novartis, Novo Nordisk, Pfizer und Sanofi erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von dem Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}